Tralokinumab ELISA Kit

Catalog No.

KDE07701

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.125 - 5,000 ng/mL

Sensitivity

33.12 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

CAT-354, CAS: 1044515-88-9

Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD., PMID:40470535

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study., PMID:40459712

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study., PMID:40459711

Suppression of Il5 and Il13 Gene Expression by Synthetic siRNA Molecules Reduces Nasal Hyperreactivity and Inflammation in a Murine Model of Allergic Rhinitis., PMID:40451198

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?, PMID:40442566

Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors., PMID:40368249

Editor's Highlights-June 2025., PMID:40322884

European Guideline (EuroGuiDerm) on atopic eczema: Living update., PMID:40317496

A Case of Cutaneous Fungal Infection Following the Administration of Dupilumab., PMID:40291282

Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis., PMID:40272773

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis., PMID:40264378

Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database., PMID:40251175

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis., PMID:40241901

Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study., PMID:40232593

[Chronic Pruritus: A Review of Its Pathophysiology and Current Treatments]., PMID:40214004

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results., PMID:40176741

Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice., PMID:40165566

A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis., PMID:40152261

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes., PMID:40142885

Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis., PMID:40130939

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years., PMID:40085349

Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics., PMID:40078859

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study., PMID:40077977

Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice., PMID:40059465

Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis., PMID:40045152

Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors., PMID:40004820

Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis., PMID:39992967

Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024., PMID:39986987

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy., PMID:39953372

Comparison chart: Interleukin (IL) receptor antagonists for atopic dermatitis., PMID:39946701

Nemolizumab (Nemluvio) for atopic dermatitis., PMID:39946696

Higher Baseline Lactate Dehydrogenase and History of Allergic Rhinitis as Predictive Factors of Conjunctivitis in Atopic Dermatitis Patients Treated with Tralokinumab., PMID:39937140

Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study., PMID:39932721

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study., PMID:39912554

Erythrodermic atopic dermatitis responding to tralokinumab after dupilumab failure., PMID:39912174

Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis., PMID:39907080

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review., PMID:39901963

Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center., PMID:39900188

Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter Experience., PMID:39899459

Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series., PMID:39878153

Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study., PMID:39864749

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study., PMID:39862316

Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis., PMID:39827864

Correction: Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis., PMID:39821857

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment., PMID:39820896

Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response., PMID:39733934

Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study., PMID:39729342

English version of clinical practice guidelines for the management of atopic dermatitis 2024., PMID:39707640

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis., PMID:39657020

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels., PMID:39673366

Document Download

Tralokinumab ELISA Kit.pdf